Bicara Therapeutics: T. Rowe Price reports 4.2% stake
The reported 4.2% position is classified under the ownership-of-5%-or-less category.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Bicara Therapeutics Inc. (BCAX) is the issuer in an ownership amendment where T. Rowe Price Investment Management, Inc. listed 2,804,772 common shares, or 4.2% of the class, as beneficially owned as of September 30, 2026. The firm reported sole voting power over 2,798,430 shares, no shared voting power, sole dispositive power over 2,804,772 shares, and no shared dispositive power; it expressly denied that the report should be construed as an admission that it is the beneficial owner.
Key Figures
Key Terms
beneficially owned regulatory
Sole Voting Power regulatory
Sole Dispositive Power regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.